A Call for Action: The Urgent Need for a National Lung Cancer Screening Programme in Brazil
A recent correspondence in The Lancet highlights the critical public health burden of lung cancer in Brazil, with over 44,000 new cases and 38,000 deaths estimated in 2022. The authors argue for the urgent implementation of a national lung cancer screening programme to address the disease’s high morbidity, mortality, and significant economic strain on the Brazilian public health system (SUS). This call to action underscores the gap in preventive care for a leading cause of cancer death and the potential for screening to improve survival rates and reduce long-term healthcare costs associated with advanced-stage diagnosis and treatment.
Study Significance: For hepatology professionals, this advocacy mirrors the ongoing push for structured screening programmes in liver disease, particularly for hepatocellular carcinoma (HCC) in high-risk patients with cirrhosis or advanced fibrosis. The Brazilian case study demonstrates the complex interplay between disease burden, healthcare economics, and policy implementation, a dynamic directly relevant to managing chronic liver conditions like NAFLD/NASH and viral hepatitis. It reinforces the strategic importance of developing cost-effective, population-based surveillance protocols to shift management from late-stage intervention to early detection, thereby improving patient outcomes and system sustainability.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
